Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

[1]  J. Neuhaus,et al.  Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. , 2016, European journal of cancer.

[2]  A. Naranjo,et al.  A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. , 2016 .

[3]  J. Raemaekers,et al.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. , 2015, The New England journal of medicine.

[4]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Bhatia.  Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors , 2015, Cancer.

[6]  S. Cohn,et al.  Second malignancies in patients with neuroblastoma: The effects of risk‐based therapy , 2015, Pediatric blood & cancer.

[7]  Sara M. Federico,et al.  Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma , 2015, Journal of pediatric hematology/oncology.

[8]  H. Shimada,et al.  Secondary malignant neoplasms after high‐dose chemotherapy and autologous stem cell rescue for high‐risk neuroblastoma , 2014, Pediatric blood & cancer.

[9]  John M Maris,et al.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[10]  W. Guo,et al.  Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck. , 2013, Carcinogenesis.

[11]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[12]  E. Gamazon,et al.  Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. , 2012, Journal of the National Cancer Institute.

[13]  H. Hakonarson,et al.  Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma , 2012, Nature Genetics.

[14]  P. Broderick,et al.  Search for inherited susceptibility to radiation-associated meningioma by genomewide SNP linkage disequilibrium mapping , 2011, British Journal of Cancer.

[15]  F. Berthold,et al.  Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. , 2011, European journal of cancer.

[16]  A. Look,et al.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. , 2010, The New England journal of medicine.

[17]  David H. Alexander,et al.  Fast model-based estimation of ancestry in unrelated individuals. , 2009, Genome research.

[18]  P. Nathan,et al.  Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. , 2009, Journal of the National Cancer Institute.

[19]  L. Qin,et al.  Reduced risk of secondary leukemia with fewer cycles of dose‐intensive induction chemotherapy in patients with neuroblastoma , 2009, Pediatric blood & cancer.

[20]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[21]  M. Hudson,et al.  Long-term Follow-up Care for Pediatric Cancer Survivors , 2009, Pediatrics.

[22]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[23]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[24]  M. Tormo,et al.  Profile of polymorphisms of drug‐metabolising enzymes and the risk of therapy‐related leukaemia , 2007, British journal of haematology.

[25]  R. Hayes,et al.  DNA Repair Gene Polymorphisms and Risk of Second Primary Neoplasms and Mortality in Oral Cancer Patients , 2005, The Laryngoscope.

[26]  S. Ben-Neriah,et al.  Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients , 2005, Leukemia.

[27]  N. Russell,et al.  Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia , 2004, Clinical Cancer Research.

[28]  C. Rubino,et al.  Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment , 2003, International journal of cancer.

[29]  C. Gambini,et al.  Second malignancies in children with neuroblastoma after combined treatment with 131I‐metaiodobenzylguanidine , 2003, Cancer.

[30]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  F. Behm,et al.  Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. B. Wilson,et al.  The Distribution of Chi-Square. , 1931, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Gwyn McClelland.  Survivors , 1891, The Hospital.

[35]  R. Arceci.  Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641 , 2012 .

[36]  R. Arceci.  The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report , 2009 .

[37]  Joseph V. Simone,et al.  Childhood cancer survivorship : improving care and quality of life , 2003 .

[38]  M. Hewitt,et al.  Childhood Cancer Survivorship , 2003 .

[39]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .